From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

SkinBioTherapeutics says it is “pleased” with a bit more dilution! Outlook potential suggests still a Buy

By HotStockRockets | Tuesday 25 February 2025


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


SkinBioTherapeutics (SBTX) has announced the issuance of 3,289,474 new shares for the exercise of warrants by David Brierwood, with CEO Stuart Ashman “pleased to continue to have the support of David Brierwood who assisted with the financing for the acquisition of Bio-Tech Solutions last year”. How ‘pleasing’ though is this really with shares in SkinBioTherapeutics currently slightly lower towards 20p in response?
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Sunday »

EZJ

BUY Easyjet

 

PDL

Petra Diamonds Remains a Short

 

Boom

Failed fund manager for PM!

 

Oil-Rig

Oilman Jim: is this legal?

Time left: 11:53:59